

1 Article

2

3 **Bayesian network enables interpretable and state-of-the-art prediction of**
4 **immunotherapy responses in cancer patients**

5

6 Hideki Hozumi,¹ Hideyuki Shimizu^{2, †}

7

8 ¹Keio University School of Medicine, Tokyo 160-8582, Japan.

9 ²Department of AI Systems Medicine, M&D Data Science Center, Tokyo Medical and Dental
10 University, Tokyo 113-8510, Japan

11

12 [†] Correspondence: h_shimizu.dsc@tmd.ac.jp (H.S.)

13

14 **Running title**

15 Bayesian network for precision medicine in lung cancer immunotherapy

16

17 **Abstract**

18 Immune checkpoint inhibitors, especially PD-1/PD-L1 blockade, have revolutionized cancer
19 treatment and brought tremendous benefits to patients who otherwise would have had a
20 limited prognosis. Nonetheless, only a small fraction of patients responds to immunotherapy,
21 and the costs and side effects of immune checkpoint inhibitors cannot be ignored. With the
22 advent of machine and deep learning, clinical and genetic data has been used to stratify
23 patient responses to immunotherapy. Unfortunately, these approaches have typically been
24 “black-box” methods that are unable to explain their predictions, thereby hindering their
25 clinical and responsible application. Herein, we developed a “white-box” Bayesian network
26 model that achieves accurate and interpretable predictions of immunotherapy responses
27 against non-small cell lung cancer (NSCLC). This Tree-Augmented naïve Bayes model (TAN)
28 precisely predicted durable clinical benefits and distinguished two clinically significant
29 subgroups with distinct prognoses. Furthermore, Our state-of-the-art white-box TAN
30 approach achieved greater accuracy than previous methods. We hope our model will guide
31 clinicians in selecting NSCLC patients who truly require immunotherapy and expect our
32 approach will be easily applied to other types of cancer.

33

34 **Keywords**

35 Bayesian network, Tree Augmented naïve Bayes, non-small cell lung cancer, immune
36 checkpoint inhibitors

37

38 **Abbreviations**

39 AUC: Area under the curve

40 BN: Bayesian network

41 DCB: Durable clinical benefit

42 HC: Hill-climbing method

43 ICIs: Immune checkpoint inhibitor

44 ML: Machine learning

45 MCMC: Markov Chain Monte Carlo

46 NB: Naïve Bayes

47 NN: Neural network

48 NSCLC: Non-small cell lung cancer

49 TAN: Tree-Augmented naïve Bayes

50 TMB: Tumor mutational burden

51

52 **Structured Abstract**

53 **Background**

54 Immune checkpoint inhibitors have revolutionized cancer treatment. Given that only a small
55 fraction of patients responds to immunotherapy, patient stratification is a pressing concern.
56 Unfortunately, the “black-box” nature of most of the proposed stratification methods, and
57 their far from satisfactory accuracy, has hindered their clinical application.

58
59 **Method**

60 We developed a “white-box” Bayesian network model, with interpretable architecture, that
61 can accurately predict immunotherapy response against non-small cell lung cancer (NSCLC).
62 We collected clinical and genetic information from several independent studies, and
63 integrated this via the Tree-Augmented naïve Bayes (TAN) approach.

64
65 **Findings**

66 This TAN model precisely predicted durable clinical benefit and distinguished two clinically
67 significant subgroups with distinct prognoses, achieving state-of-the-art performance than
68 previous methods. We also verified that TAN succeeded in detecting meaningful interactions
69 between variables from data-driven approach. Moreover, even when data have missing
70 values, TAN successfully predicted their prognosis.

71
72 **Interpretation**

73 Our model will guide clinicians in selecting NSCLC patients who genuinely require
74 immunotherapy. We expect this approach to be easily applied to other types of cancer. To
75 accelerate the uptake of personalized medicine via access to accurate and interpretable
76 models, we provide a web application (<https://pred-nsclc-ici-bayesian.shinyapps.io/Bayesian-NSCLC/>) for use by the researchers and clinicians community.

77
78
79 **Funding**

80 KAKENHI grant from the Japan Society for the Promotion of Science (JSPS) to H.S
81 (21K17856).

82

83 **Research in context**

84 **Prior evidence**

85 Many studies have advocated the use of biomarkers, such as Programmed Death Ligand-1
86 (PD-L1) and Tumor Mutational Burden (TMB), to estimate the therapeutic effect of immune
87 checkpoint inhibitors in cancer and utilize them in personalized medicine. Because such
88 single factors are insufficient, many artificial intelligence (AI)-based prediction models have
89 been developed. However, most of these have been “black box” models, in that they lack
90 interpretability. Furthermore, most of them are unable to handle missing data, which is
91 problematic because it is challenging in clinical settings to acquire all of the necessary input
92 information.

93

94 **Added valued**

95 To address this, we developed an interpretable graphical Tree-Augmented naïve Bayes (TAN)
96 model, and demonstrated its state-of-the-art “white box” performance. It achieved good
97 predictive performance, even when some of the data were missing, and identified
98 relationships between variables that were consistent with previous reports.

99

100 **Implications**

101 We present the first evidence of a specialized graphical “white-box” model that achieves
102 state-of-the-art performance in immunotherapy, providing strong support for the applicability
103 of interpretable AI models in clinical decision-making. Research using larger datasets will
104 further improve stratification and precision medicine.

105

106 Introduction

107 Lung cancer is the most prevalent cancer and the leading cause of cancer-related death in
108 men and women worldwide¹. Non-small cell lung cancer (NSCLC) accounts for nearly 85
109 percent of all lung cancers, and its five-year survival rate remains dismal, ranging from 68% in
110 patients with stage IB cancer to as low as 10% in patients with stage IVA-IVB cancer². Since
111 the invention of immune checkpoint inhibitors (ICIs), many patients have gained tremendous
112 benefits, with improved life expectancy³. For instance, nivolumab, an inhibitor of the
113 programmed cell death 1 (PD-1)/ligand (PD-L1) pathway, increased the 2-year survival rate of
114 patients with stage IIIB/IV cancer from 16% to approximately 30%⁴.

115 The decision to administer ICIs to NSCLC patients has been based primarily on the
116 expression level of PD-L1 on the surface of cancer cells, referred to as PD-L1 score⁵. In most
117 cases, patients with higher PD-L1 scores are deemed suitable candidates for ICIs.
118 Nonetheless, numerous studies have demonstrated that not all patients with higher PD-L1
119 scores respond to ICIs, and even patients with lower PD-L1 scores respond to ICIs⁵⁻⁷.
120 According to a meta-analysis of randomized controlled trials, PD-L1 expression alone was
121 insufficient to predict immunotherapy response⁷. In support of this, the PD-L1-based
122 predictive ability was reported to be 0.646 (based on the area under the curve, AUC)⁸,
123 indicating that other factors must determine immunotherapy benefits. Further, immunotherapy
124 can have devastating side-effects, particularly immune-related adverse events such as
125 pancreatitis and interstitial pneumonia⁹. The use of ICIs in patients who do not respond to
126 treatment may thus eventually reduce their life expectancy. It is therefore urgent to elucidate
127 the factors other than PD-L1 score that determine the response and prognosis of patients
128 under immunotherapy¹⁰.

129 Studies to identify factors for stratifying NSCLC patients on ICI treatment have focused on
130 the tumor mutational burden (TMB). Tumors with high TMB would contain many neoantigens
131 and generally respond well to ICIs¹⁰. However, the predictive ability of TMB was 0.601, based
132 on AUC⁸. Rather than relying on a single indicator (such as PD-L1 score or TMB) to predict
133 immunotherapy response, methods combining multiple factors have emerged. For example,
134 LIPI¹¹ and EPSILoN¹² integrate clinical data such as clinical stage, performance status, and
135 smoking status. The ratio of neutrophils to lymphocytes, a predictor of rapid progression¹⁰,
136 has been incorporated into these methods. Despite the use of multiple variables, prediction of
137 immunotherapy response rate has remained inadequate, with AUC values of 0.606 and 0.666
138 for LIPI and EPSILoN, respectively¹³. This evidence indicates that classical approaches cannot
139 provide satisfactory predictions concerning immunotherapy.

140 In recent years, machine learning (ML)-based methods have been applied to unravel the
141 factors determining the efficacy of ICI treatment for NSCLC. For one example, the AUC of a

142 neural network model that integrated several factors (TMB, PD-L1 score, mutant-allele tumor
143 heterogeneity, and immune-related pathways) was as high as 0.80 in a test cohort¹⁴. Another
144 study integrated PD-L1 score and CT images achieved an AUC of 0.76¹⁵. Other ML methods,
145 such as LightGBM, XGBoost, and regression analysis have also been investigated¹⁶. Although
146 they harness various types of information (PD-L1 score, radiological images, and clinical
147 features) as input, the AUC remains below 0.80 even for their best models, indicating that it
148 remains challenging to predict responses in ICI therapy. Moreover, ML methods, including
149 neural networks, often lack transparency due to the complexity arising from neural
150 connections and mathematical abstractions¹⁷⁻¹⁹, making it potentially impossible to explain
151 their predictions. This "black-box" nature has retarded the clinical application of established
152 models. Predictive models with higher accuracy and accountability are therefore necessary
153 for the appropriate use of ICIs in NSCLC patients.

154 With this in mind, we harnessed Bayesian theory and developed an interpretable AI model
155 with state-of-the-art predictive power about immunotherapy. Specifically, we utilized
156 Bayesian network (BN)-based models that capitulate causal relationships in the form of a
157 graphical model²⁰, allowing us to avoid the black-box problems prevalent in other ML
158 methods¹⁷. We demonstrate that a Tree-Augmented naïve Bayes (TAN) model predicts the
159 durable clinical benefit (DCB) of patients treated with ICIs with comparable or even better
160 accuracy than conventional ML methods, stratifying patients in a clinically significant manner.
161 It achieved robust predictive ability, even with limited information. This data-driven approach
162 can be used to further elucidate the factors determining immunotherapeutic responses. We
163 anticipate that our interpretable and state-of-the-art approach will expand the knowledge of
164 immunotherapy and be readily applicable to other types of cancer.

165

166 **Methods**

167 **Public cohorts**

168 The cBioPortal (<http://www.cbioportal.org>)²¹ was accessed to retrieve clinical and mutation
169 data for NSCLC patients. We chose two studies examining the effects of ICIs on NSCLC
170 patients^{8,22} to use as a dataset for this study. The inclusion criteria and clinical and mutation
171 information for the two cohorts are explained in the original papers^{8,22}.

172 The characteristics of our dataset are shown in Table 1, including age (<65 years or not),
173 gender, smoking status, and histopathological information. We excluded 25 samples,
174 comprising mostly those with unspecified histological data (described only as “NSCLC”), and
175 a few categorized as “Large Cell Neuroendocrine Carcinoma”. We obtained mutation data to
176 prepare the “frequency-based” and “evidence-based” gene-sets. For the patients in these
177 cohorts, we also analyzed progression-free status.

178

179 **Model construction**

180 The characteristic of TAN lies in its structural constraints that each explanatory variable can
181 be connected with one node other than an objective variable.

182 A complete undirected graph with nodes and edges is constructed to estimate this
183 structure. In this stage, one node is wholly connected to every other node. Each variable is
184 described as X_1, \dots, X_n , and mutual information values are given to each edge. The edge
185 weights between two nodes (X_i, X_j) are given by Equation 4:

$$186 \quad I(X_i, X_j|C) = p(X_i, X_j, C) \log \frac{p(X_i, X_j|C)}{p(X_i|C)p(X_j|C)} \dots (4)$$

187 To obtain the constrained structure of TAN from this complete graph, a structure with the
188 highest total weights under the constraint is used as an estimated structure. To transform the
189 given undirected graph tree into a directed one, a root variable is randomly chosen, and the
190 direction of the edges is set to outward from the root variable^{20,23,24}. The data were then
191 randomly split into training (2/3) and test data (1/3) (Figure 1b).

192 The training data were used to construct the models and to learn the conditional
193 probability between each node. ROC curves were constructed from the test-data predictions.
194 We constructed the model using the bnlearn (4.7.1) R package, and used the ROCR package
195 (1.0-11) for evaluation.

196

197 **Model evaluation**

198 Model-averaging methods were adopted to measure the reliability of the connections
199 between nodes in the network, by performing multiple structural estimations using the hill-
200 climbing method²³. In the Bayesian network, it is important to measure the confidence level

201 for a particular graph feature (the graph edge). This confidence level (in terms of relative
202 frequencies) referred to as arc strength^{23,25,26}, is defined as the number of times an internode
203 connection appears while generating multiple graphs; frequencies >85% are considered
204 strong²³.

205 We adopted two model-averaging methods for evaluating the node connections of our
206 model. The first is the bootstrap approach, which applies nonparametric bootstrapping to
207 generate multiple networks, and estimates the arc strength^{23,25}.

208 Algorithm 1 provides the specific method.

209

210 Algorithm 1

211 1. For $b = 1, 2, \dots, B$:

212 1.1. Sample a data set D_b from the original data D via nonparametric bootstrapping.

213 1.2. Learn the Bayesian network, $\mathcal{G}_b = (V, E_b)$ from D_b .

214 2. Estimate the arc strength, defined as follows:

215
$$\hat{p}_i = \hat{P}(a_i) = \frac{1}{B} \sum_{b=1}^B \mathbb{N}_{\{e_i \in E_b\}}$$

216 where \mathbb{N} is equal to 1 if $e_i \in E_b$ and 0 otherwise.

217

218 The second model-averaging method is the random generation of multiple graphs from a
219 uniform distribution, using the MCMC algorithm (Algorithm 2). We randomly sampled one
220 graph for every 50 graphs generated and measured arc strength from 500 sampled graphs²⁶.

221

222 Algorithm 2

223 1. For $b = 1, 2, \dots, B$:

224 1.1. Sample a data set D_b from the original data D via parametric or nonparametric
225 bootstrapping.

226 1.2. Learn the Bayesian network, $\mathcal{G}_b = (V, E_b)$ from D_b .

227 2. Estimate the arc strength, defined as follows:

228
$$\hat{p}_i = E(e_i | D) \approx \frac{1}{B} \sum_{b=1}^B \mathbb{N}_{\{e_i \in E_b\}} P(\mathcal{G}_b | D)$$

229

230 The robustness of the TAN structure estimation was evaluated by examining whether the
231 connections between nodes determined to be significant by these model-averaging methods
232 were also present in the structure of the TAN.

233

234 **Inference with limited evidence**

235 To estimate the conditional probability of an event using only the limited evidence available,
236 we used the `cpquery` function of the `bnlearn` package (4.7.1). In this method, logic sampling,
237 or an approximate inference, enables it to obtain the probability²⁷. First, a new data set is
238 created by randomly extracting data that matches the specified evidence from the whole data
239 set. In our case, patient profiles or genetic mutation information were specified. By repeating
240 this method, one million random samples are generated, and an approximate probability is
241 returned based on them.

242

243 **Survival analysis**

244 We conducted survival analysis using the `survival` package (3.3-1). $P < 0.05$ was considered
245 statistically significant.

246

247 **Data availability**

248 All clinical and mutation information is available from the cBioPortal database,
249 (<http://www.cbioportal.org>), and the specific explanation of each cohort can be obtained in
250 the original papers^{8,22}.

251 We provide a web application (<https://pred-nsclc-ici-bayesian.shinyapps.io/Bayesian-NSCLC/>) using the `shiny` package (1.7.2), providing both frequency- and evidence-based
252 models.
253

254

255 **Code availability**

256 The R code for training the NB and TAN models, and for validation and scoring via ROC and
257 survival analysis are available at GitHub (<https://github.com/Hideki-Hozumi/Prediction-with-bayesian-network.>).

258
259

260 **Results**

261 **Manual curation of clinical information related to immunotherapy**

262 To develop a state-of-the-art explanatory model, we first retrieved data for immunotherapy-
263 receiving cancer patients from cBioPortal (<http://www.cbioportal.org>), which offers clinical
264 data with mutational information²¹. Specifically, two previously published studies^{8,22} examining
265 the effect of ICIs on NSCLC patients were selected and used as a dataset for this study: the
266 Hellman cohort, comprising of 75 NSCLC patients who underwent immunotherapy²², and the
267 Rivzi cohort, of 240 NSCLC patients treated with immunotherapy⁸. In total, our dataset
268 includes 315 patients (Figure 1a). The characteristics of our dataset are shown in Table 1.

269 Among the available clinical information, we set the objective variable as DCB, which is
270 defined in the revised RECIST guideline (version 1.1) as partial response/stable disease
271 lasting >6 months²⁸. We focused on DCB because the follow-up criteria for overall survival
272 and progression-free status were inconsistent between the two cohorts^{8,22}. Given that DCB
273 has been used to assess the efficacy of immunotherapy for various tumors such as
274 melanoma²⁹ and lung cancer⁸, we believe that predicting DCB is of clinical value for stratifying
275 the patients in our study.

276 We used the three known clinical risk factors of NSCLC: age (< 65years of age or not³⁰),
277 gender, and smoking status³¹. Our model incorporated histopathological information, because
278 the pathological subtype substantially affects the prognosis³². We excluded 25 samples for
279 which there was insufficient histopathological information (Figure 1a).

280 Genetic covariates were determined in two ways. First, genes with mutation rates higher
281 than 10% in our dataset were incorporated (hereafter, the "frequency-based geneset"); these
282 include *TP53*, *KRAS*, *TTN*, *KMT2C*, *SMARCA4*, *STK11*, and *KEAP1*. Second, based on a
283 literature survey, we identified six genes (*KRAS*³³, *STK11*^{34,35}, *TP53*³⁶, *EGFR*³⁷, *ALK*³⁷, and
284 *ROS1*³⁷) associated with NSCLC-patient ICI-treatment responses or prognosis (hereafter,
285 "evidence-based geneset"). We categorized "Deletion", "in-frame deletion (IF del)",
286 "frameshift deletion (FS del)", "splice mutation (Splice)" and "Missense" modifications as
287 "Mutation" since they would likely impair the original function of the gene^{38,39}.

288 We attempted to decipher the relationships underlying DCB by combining clinical
289 characteristics with mutation data. For this purpose, we randomly divided the dataset into
290 training and test data (Figure 1a), using the former to build a model and the latter solely for
291 evaluation⁴⁰. Receiver operating characteristic (ROC) analysis was performed to evaluate
292 model performance. Survival analysis was conducted to verify the model's ability to predict
293 prognosis in addition to DCB (Figure 1b). We describe the model construction procedure in
294 the following section.

295

296 **Tree-Augmented naïve Bayes model robustly and interpretability predicted DCB**

297 We harnessed a Bayesian network graphical model to achieve accurate and interpretable
298 predictions of DCB. Bayesian networks graphically represent multivariate probability
299 distributions²⁰, and are broadly applied in various biomedical tasks, including gene network
300 feature selection⁴¹, signaling network prediction⁴², and predicting hematological malignancy
301 type⁴³. Naïve Bayes (NB) networks, the simplest type of Bayesian network, but generally
302 achieve favorable prediction accuracy⁴⁴. Based on Bayes' theorem (Equation 1), NB assumes
303 that all covariates are equally important without distinction and are conditionally independent
304 given a class value (Equation 2)⁴⁴.

$$306 \quad p(C|X_1, \dots, X_n) = \frac{p(X_1, \dots, X_n|C)p(C)}{p(X_1, \dots, X_n)} \Leftrightarrow \text{Posterior} = \frac{\text{Prior} \times \text{Likelihood}}{\text{Evidence}} \dots (1)$$

$$307 \quad p(C|X_1, \dots, X_n) \propto p(C) \prod_{k=1}^n p(X_k|C) \dots (2)$$

308 The probability associated with a parent node (objective variable) is described as $p(C)$, and
309 the probability is updated to $p(C|X_1, \dots, X_n)$ when explanatory information from child nodes
310 (X_1, \dots, X_n) is provided. In terms of its network structure, arrows (directed edges) extend from
311 one node (a parent node or objective variable) to all other nodes (child nodes) (Supplementary
312 Figure 1a). Despite its simple design and assumptions, NB achieves much better
313 classification than expected, and is used in medical data analysis⁴⁵. Nonetheless, in its
314 original form, it depends relatively heavily on the assumption that the covariates are
315 statistically independent, hampering its application to real-world biomedical data.
316 To address this, we utilized Tree-Augmented naïve Bayes models (hereafter, "TAN"; Equation
317 3):

$$319 \quad p(C|X_1, \dots, X_n) \propto p(C) \cdot p(X_1|C) \cdot p(X_2|X_k, C) \cdot \dots \cdot p(X_n|X_l, C) \dots (3)$$

321 TAN alleviates the conditional independence between features, while keeping the directed
322 acyclic graph simpler than in conventional neural network models (Supplementary Figure 1b,
323 1c). TAN does not assume conditional independence, partially allowing dependent
324 relationships between variables (Equation 3)⁴⁶. Therefore, because it can express a greater
325 number of states, TAN must outperform NB model. Indeed, it has been applied in numerous
326 biomedical tasks, including risk stratification in pulmonary hypertension⁴⁷, and
327 mammography⁴⁸, achieving high accuracy. Here, we used NB and TAN to establish predictive

328 models with higher accuracy and interpretability, and compared their ability to predict DCB in
329 NSCLC patients.

330 First, we constructed frequency-based models, using clinical data and seven genes from
331 the frequency-based geneset (*TP53*, *KRAS*, *TTN*, *KMT2C*, *SMARCA4*, *STK11*, and *KEAP1*) as
332 covariates. The structure of frequency-based NB is shown in Figure 2a. TAN structure was
333 estimated using a training dataset (Figure 2b). For the NB model, the area under the curve
334 (AUC) was 0.686 for the training dataset and 0.726 for the test dataset. (Figure 2c); for the
335 TAN model, these values were 0.836 and 0.728, respectively (Figure 2d). These results
336 indicate that the TAN model has comparable or greater predictive accuracy than the NB
337 model.

338 We next constructed evidence-based NB (Figure 2e) and TAN (Figure 2f) models, using
339 clinical information and six genes from the evidence-based geneset (*KRAS*, *STK11*, *TP53*,
340 *EGFR*, *ALK*, and *ROS1*) as covariates, using the same approach used for the frequency-
341 based models. Using the test dataset, the NB and TAN AUCs were 0.712 (Figure 2g) and
342 0.823 (Figure 2h), respectively, suggesting that TAN outperformed NB.

343 These lines of evidence demonstrate that the optimized TAN model outperforms NB, and
344 robustly predicts DCB via frequency- and evidence-based approaches.

345 Its performance is comparable to that of other cutting-edge methods^{15,49,50}, while retaining
346 explainability.

347

348 **Optimized TAN yields a robust graphical structure**

349 We next evaluated the robustness of the structural estimation of our model in immunotherapy.
350 We statistically generated multiple directed acyclic graphs (DAGs): significant edges
351 (internode connections) were detected when it appeared in >85% of the graphs.

352 We used two model-averaging methods^{25,51} to determine if the relationships identified by
353 our methodology (Figure 2b for the frequency-based model and Figure 2f for the evidence-
354 based model, respectively) were sufficiently robust. We performed bootstrap sampling²⁵ and
355 Markov chain Monte Carlo (MCMC) methods to randomly constructed DAGs from a uniform
356 distribution, as previously reported⁵¹. This revealed several significant connections (Table 2,
357 Figure 3a, 3b for the frequency-based model; Table 3, Figure 3c, 3d for the evidence-based
358 model). These results demonstrate that the model-averaging methods produce similar
359 architectures, indicating that our method robustly discovers crucial relationships governing
360 the immunotherapy response.

361

362 **Our TAN model stratifies and inferences even with limited clinical information**

363 Patient stratification is crucial to the development of personalized medicine⁵². We thus
364 evaluated our model's applicability to the stratification of NSCLC patients. We obtained the
365 progression-free status of the patients in our dataset from the cBioPortal database^{8,22}. Our
366 models identified two distinct and clinically significant groups based on binary prediction
367 (Figure 4a for the frequency-based model and Figure 4b for the evidence-based model).

368 Importantly, the optimized TAN model can handle missing data and calculate conditional
369 probabilities. For instance, it can predict whether a tumor will respond to immunotherapy,
370 even if all we know about a particular NSCLC patient is that they have *TP53* and *STK11*
371 mutations; the estimated response probability is 0.163, indicating that this patient would not
372 benefit substantially from ICIs (Figure 5). This speculation is consistent with established
373 evidence³³. In contrast, for a young female patient with a *KMT2C* mutation, but no *STK11* and
374 *TP53* mutations, the estimated ICI response probability is 0.592, indicating that ICI treatment
375 would be valuable. Previous models, including those based on ML and deep learning
376 methods, cannot adequately handle missing data, requiring all of the necessary information⁵³.
377 Given that data acquisition can be laborious, particularly in clinical settings, our model may
378 help clinicians in decision-making, especially in data-limited situation.

379

380

381 **Discussion**

382 Most prior attempts to predict immunotherapy responses have used ML-based approaches¹⁴⁻
383 ¹⁶, which are complex “black-box” systems that cannot handle missing data. As input, they
384 require all of the necessary clinical and molecular information to be provided. Such data are
385 often difficult to obtain, especially in hospitals with limited resources, hampering the clinical
386 application of these models.

387 Transparency and clinical validation are necessary to achieve trustable medical AI¹⁷.
388 Therefore, we sought to develop an interpretable and robust model that predicts NSCLC
389 patient responses to immunotherapy. We used clinical information, selected mutation data
390 based on the frequency and evidence-based approaches, and established optimized TAN
391 models. Our approach is comparable with, or even superior to, several cutting-edge ML-
392 based methods^{15,49,50}, while retaining explainability. It provides clinically informative
393 predictions even when data are limited (Figure 5), as is quite common in clinical settings.
394 Furthermore, because this model only computes conditional probabilities based on Bayes'
395 theorem²⁵, it is possible, if necessary, to control which nodes should have (or should not) have
396 connections, using a “white list” (or “black list”) based on expert knowledge.

397 We selected several genes based on the mutation frequency or previous evidence. *KRAS*,
398 an immunomodulatory oncogenic gene, leads to escape from immunotherapy³⁴. Together

399 with *TP53* or *STK11* mutations, *KRAS* mutation is a potent prognostic factor^{33,36}. *STK11* is
400 associated with diminished immunotherapy response³⁵. *BRAF* mutation, which are associated
401 with a higher tumor burden, may make tumors vulnerable to immunotherapy⁵⁴. Mutations in
402 driver oncogenes such as *EGFR*, *ALK*, and *ROS1* in tumors cause a lack of immunogenicity,
403 and thus, a poor response to immunotherapy, regardless of PD-L1 score⁵⁵. Therefore, the
404 expert consensus suggests that patients with these mutations should not be treated with
405 immunotherapy⁵.

406 Our models could also be used to generate intriguing hypotheses for future research. For
407 instance, our inferences based on limited data (Figure 5) are consistent with the findings of
408 recent reports^{33,35}. This suggests that, by using more clinical samples with diverse genetic
409 profiles, our approach may reveal new targets in immunotherapy, providing an invaluable
410 resource for both clinical and basic medicine.

411 Consistent with an earlier analysis of clinical data on the utility of TAN⁴⁸, our TAN-based
412 approach provided greater value than the NB model. Because of the small sample, the
413 conventional NB model using hill-climbing methods were unable to construct suitable
414 structures for inference (Supplementary Figure 2), suggesting that our approach is better
415 suited to inference with a small dataset. TAN alleviates the conditional constraints imposed by
416 NB. Here, some of the essential connections in TAN structural learning were also detected via
417 model-averaging using bootstrap sampling and MCMC (Figure 3). Our model-averaging
418 findings obtained using the frequency-based approach (Figure 3a, 3b), for instance, strongly
419 suggest an association between smoking status and *KRAS* mutation, which has been
420 established in a previous report³⁷. Other strong connections between nodes inferred by
421 model-averaging method (Figure 3) are expected to reveal immunotherapy-related hidden
422 relationships.

423 In terms of potential limitations, we cannot rule out selection bias due to the integrated use
424 of public datasets. Although the datasets comprise patients who underwent immunotherapy,
425 it is plausible that the data do not represent a specific population. In addition, the strength of
426 the internode relationships that we estimated may reflect the small sample size, and an
427 analysis employing a larger dataset may reveal additional relationships. We therefore
428 developed a web-based intuitive DCB estimator ([https://pred-nsclc-ici-
429 bayesian.shinyapps.io/Bayesian-NSCLC/](https://pred-nsclc-ici-bayesian.shinyapps.io/Bayesian-NSCLC/)) that does not require computational expertise.
430 Future analyses with larger clinical samples are likely to overcome these limitations, and
431 provide further support for the validity of this approach.

432 In summary, these robust models are comparable with, or even superior to, other
433 predictive models for immunotherapy. They can predict meaningful and interpretable
434 connections and inferences, even with a limited number of observations. We hope that this

435 model will guide clinicians in selecting NSCLC patients who require immunotherapy, and
436 expect it to be easily applied to other types of cancer.
437

438 **Acknowledgements**

439 This work was supported by KAKENHI grants from the Japan Society for the Promotion of
440 Science (JSPS) to H.S. (21K17856). We thank our laboratory members for discussion.

441

442 **Contributions**

443 H.H. and H.S. designed the project. H.H. contributed to formal analyses and interpretation.
444 H.H. wrote the draft version of the manuscript. H.S. supervised the study and edited the
445 manuscript. All authors contributed to the article and approved the final version.

446

447 **Competing interests**

448 The authors declare no competing interests.

449

450 **References**

- 451 1. Ganti, A. K., Klein, A. B., Cotarla, I., Seal, B. & Chou, E. Update of incidence,
452 prevalence, survival, and initial treatment in patients with non-small cell lung cancer in
453 the US. *JAMA Oncol.* **7**, 1824–1832 (2021).
- 454 2. Duma, N., Santana-Davila, R. & Molina, J. R. Non-small cell lung cancer: Epidemiology,
455 screening, diagnosis, and treatment. *Mayo Clin Proc.* **94**, 1623–1640 (2019).
- 456 3. Zhang, Y. & Zhang, Z. The history and advances in cancer immunotherapy:
457 Understanding the characteristics of tumor-infiltrating immune cells and their
458 therapeutic implications. *Cell Mol Immunol.* **17**, 807–821 (2020).
- 459 4. Horn, L. *et al.* Nivolumab versus docetaxel in previously treated patients with advanced
460 non-small-cell lung cancer: Two-year outcomes from two randomized, open-label,
461 phase III Trials (CheckMate 017 and CheckMate 057). *Journal of Clinical Oncology* **35**,
462 3924–3933 (2017).
- 463 5. Brahmer, J. R. *et al.* The Society for Immunotherapy of Cancer consensus statement on
464 immunotherapy for the treatment of non-small cell lung cancer (NSCLC). *J Immunother*
465 *Cancer.* **6**, 75 (2018).
- 466 6. Yu, H., Boyle, T. A., Zhou, C., Rimm, D. L. & Hirsch, F. R. PD-L1 Expression in lung
467 cancer. *J Thorac Oncol.* **11**, 964–975 (2016).
- 468 7. Shen, X. & Zhao, B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in
469 cancer: meta-analysis. *BMJ.* **362**, k3529 (2018).
- 470 8. Rizvi, H. *et al.* Molecular determinants of response to anti-programmed cell death (PD)-
471 1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell
472 lung cancer profiled with targeted next-generation sequencing. *J Clin Oncol.* **36**, 633–
473 641 (2018).
- 474 9. Martins, F. *et al.* Adverse effects of immune-checkpoint inhibitors: Epidemiology,
475 management and surveillance. *Nat Rev Clin Oncol.* **16**, 563–580 (2019).
- 476 10. Brueckl, W. M., Ficker, J. H. & Zeitler, G. Clinically relevant prognostic and predictive
477 markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer
478 (NSCLC). *BMC Cancer.* **20**, 1185 (2020).
- 479 11. Mezquita, L. *et al.* Association of the lung immune prognostic index with immune
480 checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.
481 *JAMA Oncol.* **4**, 351–357 (2018).
- 482 12. Prelaj, A. *et al.* EPSILoN: A prognostic score using clinical and blood biomarkers in
483 advanced non-small-cell lung cancer treated with immunotherapy. *Clin Lung Cancer.*
484 **21**, 365-377.e5 (2020).

- 485 13. Zhao, Q. *et al.* Three models that predict the efficacy of immunotherapy in Chinese
486 patients with advanced non-small cell lung cancer. *Cancer Med.* **10**, 6291–6303 (2021).
- 487 14. Jiang, J. *et al.* Robust prediction of immune checkpoint inhibition therapy for non-small
488 cell lung cancer. *Front Immunol.* **12**, 646874 (2021).
- 489 15. Tian, P. *et al.* Assessing PD-L1 expression in non-small cell lung cancer and predicting
490 responses to immune checkpoint inhibitors using deep learning on computed
491 tomography images. *Theranostics.* **11**, 2098–2107 (2021).
- 492 16. Ahn, B. C. *et al.* Clinical decision support algorithm based on machine learning to
493 assess the clinical response to anti-programmed death-1 therapy in patients with non-
494 small-cell lung cancer. *Eur J Cancer.* **153**, 179–189 (2021).
- 495 17. Quinn, T. P., Jacobs, S., Senadeera, M., Le, V. & Coghlan, S. The three ghosts of
496 medical AI: Can the black-box present deliver? *Artif Intell Med.* **124**, 102158 (2022).
- 497 18. Amann, J., Blasimme, A., Vayena, E., Frey, D. & Madai, V. I. & Precise4Q consortium.
498 Explainability for artificial intelligence in healthcare: a multidisciplinary perspective. *BMC*
499 *Med Inform Decis Mak.* **20**, 310 (2020).
- 500 19. Castelvechi, D. Can we open the black box of AI? *Nature* **538**, 20–23 (2016).
- 501 20. Friedman, N., Geiger, D. & Goldszmidt, M. Bayesian Network Classifiers. *Mach Learn.*
502 **29**, 131–163 (1997).
- 503 21. Cerami, E. *et al.* The cBio cancer genomics portal: an open platform for exploring
504 multidimensional cancer genomics data. *Cancer Discov.* **2**, 401–404 (2012).
- 505 22. Hellmann, M. D. *et al.* Genomic features of response to combination immunotherapy in
506 patients with advanced non-small-cell lung cancer. *Cancer Cell.* **33**, 843–852.e4 (2018).
- 507 23. Scutari, M. & Denis, J.-B. *Bayesian Networks: With Examples in R. Chapman and*
508 *Hall/CRC* (Chapman and Hall/CRC, 2021).
- 509 24. Cheng, J. & Greiner, R. Comparing Bayesian network classifiers. *CoRR.* **1301**, 6684
510 (2013).
- 511 25. Friedman, N., Goldszmidt, M. & Wyner, A. Data analysis with Bayesian networks: A
512 bootstrap approach. *CoRR.* **1301**, 6695 (2013).
- 513 26. Friedman, N. & Koller, D. Being Bayesian about network structure. A Bayesian approach
514 to structure discovery in Bayesian networks. *Machine Learning.* **50**, 95–125 (2003).
- 515 27. Henrion, M. Propagating Uncertainty in Bayesian Networks by Probabilistic Logic
516 Sampling. *Machine Intelligence and Pattern Recognition.* **5**, 149–163 (North-Holland,
517 1988).
- 518 28. Eisenhauer, E. A. *et al.* New response evaluation criteria in solid tumours: Revised
519 RECIST guideline (version 1.1). *Eur J Cancer.* **45**, 228–247 (2009).

- 520 29. Kaufman, H. L. *et al.* Durable response rate as an endpoint in cancer immunotherapy:
521 Insights from oncolytic virus clinical trials. *J Immunother Cancer*. **5**, 72 (2017).
- 522 30. Huo, G., Liu, W. & Chen, P. Inhibitors of PD-1 in non-small cell lung cancer: A meta-
523 analysis of clinical and molecular features. *Front Immunol*. **13**, 875093 (2022).
- 524 31. Schabath, M. B. & Cote, M. L. Cancer Progress and priorities: Lung cancer. *Cancer*
525 *Epidemiol Biomarkers Prev*. **28**, 1563–1579 (2019).
- 526 32. Balata, H. *et al.* Predicting survival following surgical resection of lung cancer using
527 clinical and pathological variables: The development and validation of the LNC-PATH
528 score. *Lung Cancer*. **125**, 29–34 (2018).
- 529 33. La Fleur, L. *et al.* Mutation patterns in a population-based non-small cell lung cancer
530 cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
531 *Lung Cancer*. **130**, 50–58 (2019).
- 532 34. Hamarsheh, S., Groß, O., Brummer, T. & Zeiser, R. Immune modulatory effects of
533 oncogenic KRAS in cancer. *Nat Commun*. **11**, 5439 (2020).
- 534 35. Skoulidis, F. *et al.* STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-
535 mutant lung adenocarcinoma. *Cancer Discov*. **8**, 822–835 (2018).
- 536 36. Xu, F. *et al.* A TP53-associated gene signature for prediction of prognosis and
537 therapeutic responses in lung squamous cell carcinoma. *Oncoimmunology*. **9**, 1731943
538 (2020).
- 539 37. Chapman, A. M., Sun, K. Y., Ruestow, P., Cowan, D. M. & Madl, A. K. Lung cancer
540 mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and
541 ever smokers. *Lung Cancer*. **102**, 122–134 (2016).
- 542 38. Lea, I. A. *et al.* Genetic pathways and mutation profiles of human cancers: site- and
543 exposure-specific patterns. *Carcinogenesis*. **28**, 1851–1858 (2007).
- 544 39. Bardelli, A. & Velculescu, V. E. Mutational analysis of gene families in human cancer.
545 *Curr Opin Genet Dev*. **15**, 5–12 (2005).
- 546 40. Raschka, S. Model evaluation, model selection, and algorithm selection in machine
547 learning. *CoRR*. **1811**, 12808 (2018).
- 548 41. Lan, Z., Zhao, Y., Kang, J. & Yu, T. Bayesian network feature finder (BANFF): an R
549 package for gene network feature selection. *Bioinformatics*. **32**, 3685–3687 (2016).
- 550 42. Qin, T., Tsoi, L. C., Sims, K. J., Lu, X. & Zheng, W. J. Signaling network prediction by
551 the Ontology Fingerprint enhanced Bayesian network. *BMC Syst Biol*. **6**, S3 (2012).
- 552 43. Agrahari, R. *et al.* Applications of Bayesian network models in predicting types of
553 hematological malignancies. *Sci Rep*. **8**, 6951 (2018).
- 554 44. Webb, G. I. Naïve Bayes. in *Encyclopedia of Machine Learning* (eds. Sammut Claude &
555 and Webb, G. I.) 713–714 (Springer US, 2010).

- 556 45. Kononenko, I. Machine learning for medical diagnosis: History, state of the art and
557 perspective. *Artif Intell Med.* **23**, 89–109 (2001).
- 558 46. Zheng Fei & and Webb, G. I. Tree Augmented Naive Bayes. in *Encyclopedia of Machine*
559 *Learning* (eds. Sammut Claude & and Webb, G. I.) 990–991 (Springer US, 2010).
- 560 47. Kanwar, M. K. *et al.* Risk stratification in pulmonary arterial hypertension using Bayesian
561 analysis. *Eur Respir J.* **56**, 2000008 (2020).
- 562 48. Burnside, E. S. *et al.* Probabilistic computer model developed from clinical data in
563 national mammography database format to classify mammographic findings. *Radiology.*
564 **251**, 663–672 (2009).
- 565 49. He, B. X. *et al.* Deep learning for predicting immunotherapeutic efficacy in advanced
566 non-small cell lung cancer patients: a retrospective study combining progression-free
567 survival risk and overall survival risk. *Transl Lung Cancer Res.* **11**, 670–685 (2022).
- 568 50. Ouyang, W. *et al.* A prognostic risk score based on hypoxia-, immunity-, and
569 epithelial-to-mesenchymal transition-related genes for the prognosis and
570 immunotherapy response of lung adenocarcinoma. *Front Cell Dev Biol.* **9**, 758777
571 (2022).
- 572 51. Ide, J. S. & Cozman, F. G. Testing MCMC algorithms with randomly generated Bayesian
573 networks. *Machine Intelligence and Pattern Recognition.* **5**, 149–163 (2002).
- 574 52. Wang, M., Herbst, R. S. & Boshoff, C. Toward personalized treatment approaches for
575 non-small-cell lung cancer. *Nat Med.* **27**, 1345–1356 (2021).
- 576 53. Holzinger, A., Langs, G., Denk, H., Zatloukal, K. & Müller, H. Causability and
577 explainability of artificial intelligence in medicine. *Wiley Interdiscip Rev Data Min Knowl*
578 *Discov.* **9**, e1312 (2019).
- 579 54. Negrao, M. v. *et al.* Oncogene-specific differences in tumor mutational burden, PD-L1
580 expression, and outcomes from immunotherapy in non-small cell lung cancer. *J*
581 *Immunother Cancer.* **9**, e002891 (2021).
- 582 55. Blons, H., Garinet, S., Laurent-Puig, P. & Oudart, J. B. Molecular markers and
583 prediction of response to immunotherapy in non-small cell lung cancer, an update. *J*
584 *Thorac Dis.* **11**, S25–S36 (2019).

585
586
587

588 **Tables**

589 **Table 1. Characteristics of the dataset**

Characteristic	Numbers
Age	
≥ 65	157
< 65	133
Histopathology	
Adenocarcinoma	256
Squamous	34
Gender	
Male	141
Female	149
Smoker	
Ever	231
Never	59
DCB	
Yes	99
No	191
<i>TP53</i>	
Mutation	168
No Mutation	122
<i>KRAS</i>	
Mutation	100
No Mutation	190
<i>STK11</i>	
Mutation	50
No Mutation	240
<i>KEAP1</i>	
Mutation	47
No Mutation	243
<i>TTN</i>	
Mutation	34
No Mutation	256
<i>KMT2C</i>	

Mutation	32	590
No Mutation	258	
SMARCA4		
Mutation	30	
No Mutation	260	
EGFR		
Mutation	26	
No Mutation	264	
ALK		
Mutation	13	
No Mutation	277	
ROS1		
Mutation	7	
No Mutation	283	

591

592

593
594

Table 2. Node verification via bootstrapping and MCMC for the frequency-based model

Methods	Connection	Strength	TAN model
Bootstrap	Smoker- <i>KRAS</i>	0.956	○
	Smoker- <i>KMT2C</i>	0.874	○
	<i>TP53-KRAS</i>	0.990	○
	<i>KRAS-Cancer</i>	0.968	○
	<i>TTN-Cancer</i>	0.854	×
	<i>STK11-KEAP1</i>	1.000	○
MCMC	<i>Cancer-KRAS</i>	1.000	○
	Smoker-Age	0.878	○
	Smoker- <i>TP53</i>	0.982	×
	Smoker- <i>KRAS</i>	0.982	○
	Smoker- <i>KEAP1</i>	0.962	○
	<i>KRAS-TP53</i>	1.000	○
	<i>TTN-Cancer</i>	0.978	×
	<i>TTN-KMT2C</i>	0.868	×
	<i>TTN-SMARCA4</i>	0.974	×
	<i>STK11-TP53</i>	0.978	×
	<i>KEAP1-SMARCA4</i>	0.970	×
	<i>KEAP1-STK11</i>	1.000	○

595
596


597 **Table 3. Node verification via bootstrapping and MCMC for the evidence-based model**
 598

Methods	Connection	Strength	TAN model
Bootstrap	Cancer- <i>KRAS</i>	0.978	○
	Cancer- <i>ROS1</i>	0.880	×
	Smoker- <i>TP53</i>	0.942	×
	Smoker- <i>EGFR</i>	0.872	○
	<i>KRAS-TP53</i>	1.000	○
	<i>STK11-TP53</i>	0.847	○
	<i>ALK-ROS1</i>	0.956	○
MCMC	Smoker- <i>KRAS</i>	0.958	○
	Smoker- <i>STK11</i>	0.980	×
	Smoker- <i>TP53</i>	0.998	×
	Smoker- <i>EGFR</i>	0.908	○
	<i>KRAS-Cancer</i>	1.000	○
	<i>KRAS-TP53</i>	1.000	○
	<i>STK11-TP53</i>	1.000	○
	<i>ALK-EGFR</i>	0.942	×
	<i>ROS1-Cancer</i>	1.000	×
	<i>ROS1-ALK</i>	0.970	○

599
600

601 **Figures and figure legends**

602



Hozumi et al., Figure 1

603


604

605 **Figure 1. Workflow of the study**

606 (a) We obtained clinical and genetic data of non-small cell lung cancer (NSCLC) patients from
607 cBioPortal (<http://www.cbioportal.org>). There were 315 data samples, of which 25 samples
608 were excluded because they had insufficient histopathology data, or because the disease
609 were rare. Two-thirds of the data was used to construct the models (train data), and the rest
610 was used for evaluation (test data).


611 (b) We developed the naïve Bayes (NB) and Tree-Augmented naïve Bayes (TAN) models and
612 evaluated their predictive accuracy for whether patients will benefit from immunotherapy. We
613 performed survival analyses to compare the two groups based on the binary predictions by
614 TAN model.

615



Hozumi et al., Figure 2

617 **Figure 2. Bayesian network predicted the benefit of immunotherapy with high accuracy.**
618 **(a, b)** The naïve Bayes (NB, **a**) and Tree-Augmented naïve Bayes (TAN, **b**) models were trained
619 using the frequency-based dataset. The predictor variable “Benefit” (DCB, shown in red) is
620 defined in the RECIST guideline (version 1.1)²⁸. Explanatory variables include patient data
621 (yellow), tumor tissue information (orange), and the frequency-gene dataset (green). **(c, d)**
622 Predictive performance of the frequency-based models (**a, b**) for the test dataset. TAN
623 achieved greater accuracy than NB in terms of the Area Under the Curve (AUC), and was
624 comparable to, or even more accurate than, state-of-the-art methods^{15,49,50}. **(e, f)** The naïve
625 Bayes (NB, **e**) and Tree-Augmented naïve Bayes (TAN, **f**) models were trained using the
626 evidence-based dataset. **(g, h)** Predictive performance of the evidence-based models (**e, f**) in
627 the test dataset. TAN was more accurate than NB in terms of AUC, and comparable to, or
628 even more accurate than, state-of-the-art methods^{15,49,50}.
629





Hozumi et al., Figure 3

630

631 **Figure 3. Evaluating the validity of the structure estimated by TAN through model-**
 632 **averaging methods**

633 The linkages between nodes estimated by TAN were validated using model-averaging
 634 methods (bootstrap and MCMC). (a, b) Bootstrap (a) and MCMC (b) sampling was used to
 635 create models using frequency-based datasets; connections considered to be significant in
 636 each process are illustrated. Relationships detected by the model-averaging methods but not
 637 by TAN are shown in red. Connections detected both by model-averaging methods and TAN
 638 are in black. (c, d) Bootstrap (c) and MCMC (d) sampling was used to create models using
 639 evidence-based datasets; connections considered to be significant in each process are
 640 illustrated. The dependencies among variables estimated by TAN included many of the
 641 connections detected by model-averaging methods, indicating the robustness of our models.
 642 See also Tables 2 and 3.


643




Hozumi et al., Figure 4

645 **Figure 4. Our TAN-based interpretable models stratify NSCLC patient prognosis**
646 **(a, b)** We tested whether these TAN models are suitable for stratifying progression-free
647 survival. We classified patients into two groups (durable clinical benefit “DCB”, and “non-
648 DCB”) based on the binary predictions of the frequency-based **(a)** or evidence-based **(b)**
649 models, and estimated progression-free survival status of the patients in our dataset via the
650 Kaplan-Meier method. The p -values shown in this figure are from log-rank tests.
651

a



b



Hozumi et al., Figure 5

653 **Figure 5. The optimized TAN model can infer DCB even from limited data**

654 **(a, b)** We investigated whether our model (frequency-based TAN, for instance) could infer the
655 durable clinical benefit (DCB) from limited information. **(a)** In this example, the only information
656 provided to the model was the *TP53* and *STK11* mutations in the patient. **(b)** Using rejection
657 sampling, and approximate inference of the probability distribution of the unknown
658 information, we were able to obtain probabilities for all of the hidden states. From only the
659 information that *TP53* and *STK11* are co-mutated, the model computed a response
660 probability to be 0.163, suggesting that immunotherapy would not be effective for this patient,
661 consistent with the previous reports³³. The white boxes and DCB status were calculated using
662 our approach.